Dermatitis

Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs

Retrieved on: 
Friday, May 5, 2023

Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.

Key Points: 
  • Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Librela™ (bedinvetmab injection) for the control of pain associated with osteoarthritis (OA) in dogs.
  • Librela is the first and only once-monthly, anti-NGF monoclonal antibody treatment for canine OA pain and is approved as safe and effective in providing long-term control of OA pain symptoms in dogs, which can improve their mobility and overall quality of life.
  • The pain of OA can impact a dog’s physical and emotional health.
  • This once monthly injection works differently from other pain medications – it’s unique mode of action targets Nerve Growth Factor (NGF), a key component of OA pain.

Women's Exposure to Domestic Violence Associated with Risk of Developing Atopic Diseases

Retrieved on: 
Friday, May 5, 2023

MILWAUKEE, May 5, 2023 /PRNewswire-PRWeb/ -- Being a woman exposed to domestic violence and abuse is positively associated with the development of atopic disease, with the association strongest for asthma development, according to research published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice), a journal of the American Academy of Allergy, Asthma & Immunology (AAAAI).

Key Points: 
  • "After adjusting for possible cofounders, our results show women with a recorded exposure to domestic violence and abuse had a 52% increased risk of developing atopic diseases," said Dr Joht Singh Chandan, PhD, corresponding author of the study.
  • "We set out to deepen our understanding of the health impacts of domestic violence so evidence-based public health policies can be further developed to address not only domestic violence, but secondary effects like the development of atopic diseases," Dr. Chandan said.
  • A total of 13,852 women were identified as being exposed to domestic violence and were matched to 49,036 similar women without a reported exposure.
  • If you or someone you know is experiencing domestic violence, visit the National Domestic Violence Hotline website or contact their hotline at 1-800-799-7233 for assistance.

A Simple Antibacterial Treatment Solves a Severe Skin Problem Caused by Radiation Therapy

Retrieved on: 
Thursday, May 4, 2023

BRONX, N.Y., May 4, 2023 /PRNewswire/ -- Acute radiation dermatitis (ARD)—characterized by red, sore, itchy or peeling skin—affects up to 95% of people undergoing radiation treatment for cancer. Severe cases can cause significant swelling and painful skin ulcers that can severely impair quality of life, yet little is known about why this condition occurs and no standardized treatments for preventing severe ARD have been widely adapted.

Key Points: 
  • Researchers at Montefiore Einstein Cancer Center (MECC) have found that many cases of ARD involve a common skin bacterium and that a simple, low-cost treatment can prevent severe cases, potentially setting a new standard of care for people undergoing radiation therapy.
  • Each year, 10 million people are treated with radiation therapy to reduce the size of their tumors.
  • Radiation weakens the skin's structure at the treatment site and can result in infection by allowing SA to break through the skin's outer layer.
  • In one of the JAMA Oncology studies, the MECC researchers enrolled 76 patients undergoing radiation therapy for cancer.

Tulips for breakfast: the flower as food from the war to contemporary gastronomy

Retrieved on: 
Wednesday, May 3, 2023

Trains and river transport were blocked by rivers that had frozen over so people found it more difficult to access food.

Key Points: 
  • Trains and river transport were blocked by rivers that had frozen over so people found it more difficult to access food.
  • Calorie consumption went from 1,800 to 500 kilocalories per person per day from May 1944 to February 1945.
  • It is estimated that from the fall of 1944 until May 1945, between 20,000 and 25,000 Dutch citizens died of malnutrition.

Tulip soup to soothe the soul

    • During this stage of war, tulips were no longer cultivated and a large reserve of unplanted bulbs remained.
    • Tulip bulb soup was cooked during the only hour of gas that was available per day.
    • Although tulip bulbs are rich in starch, they will not thicken the soup as flour does.

Toxic bulbs

    • Their bulbs mainly contain an allergen: the compound called tulipalin A, which is primarily found in the bulb’s outer layer, but also in the stem, leaves and petals.
    • Experts have detected the poisoning of cows which have eaten hay and tulip bulbs, in addition to the compound’s role as a causative agent of so-called “tulip fingers”.
    • The danger of consuming tulip bulbs lies in the variety or in the way in which they are prepared.

In modern cuisine

    • The ornamental use of sugared petals on a cake or eating them with syrup is also noteworthy.
    • Caron invented dishes such as tomato confit, fennel and tulip bulb salad and oysters with tulip bulbs.
    • The Dutch bulb industry paid tribute to her by naming a white variety of the flower with exceptional luminosity, the Audrey Hepburn tulip.

Rubedo Life Sciences Announces Nomination of First-in-Class Disease-Modifying Candidate RLS-1496 in Dermatology at LSX World Congress 2023

Retrieved on: 
Wednesday, May 3, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230503005464/en/
    Marco Quarta, Ph.D., CEO & Co-Founder, Rubedo Life Sciences presenting at LSX World Conference 2023.
  • (Photo: Business Wire)
    RLS-1496 is a disease-modifying therapy with the potential for superiority over standard of care in multiple chronic skin indications.
  • Rubedo’s R&D program in dermatology was initiated in Q4 2021, and effective progression from target discovery to candidate nomination took one and a half years.
  • ALEMBIC™ Senescence Signatures were utilized to analyze skin samples derived from patients with chronic dermatological conditions, such as dermatitis and psoriasis.

Arcutis Completes Enrollment in INTEGUMENT-PED Pivotal Phase 3 Trial of Roflumilast Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5

Retrieved on: 
Tuesday, May 2, 2023

Arcutis previously reported positive topline data in similarly designed Pivotal Phase 3 trials of roflumilast cream 0.15% in ages 6 and above.

Key Points: 
  • Arcutis previously reported positive topline data in similarly designed Pivotal Phase 3 trials of roflumilast cream 0.15% in ages 6 and above.
  • “Topical steroids are the first-line of treatment for AD in children, and there are few treatment options available for chronic use.
  • “Roflumilast cream is a once-daily, steroid free treatment that was formulated to be a non-greasy, moisturizing cream that absorbs quickly.
  • Arcutis plans to submit the new drug application (NDA) for roflumilast cream 0.15% for adults and children age 6 and older in the second half of 2023.

Beyond the Eurovision Stage with TARAMAR Skincare

Retrieved on: 
Tuesday, May 2, 2023

REYKJAVIK, iceland, May 2, 2023 /PRNewswire/ -- TARAMAR, an award-winning beauty brand from Iceland is proud to be supporting Icelandic singer Diljá on her Eurovision 2023 journey. The company strongly believes in supporting young artists on their way to success. 

Key Points: 
  • The young star is a big fan of TARAMAR's natural and organic skincare line and the amazing benefits that pure Icelandic skincare delivers.
  • A spokesperson at TARAMAR said, "At TARAMAR, we know how stressful it can be being in the spotlight and the public eye.
  • To celebrate this epic event and collaboration, TARAMAR is proud to announce the launch of the TARAMAR Eurovision Gift Box .
  • Together with careful cultivation of plants and organic farming, the TARAMAR formulas may be among the purest skincare formula on the market.

Beyond the Eurovision Stage with TARAMAR Skincare

Retrieved on: 
Tuesday, May 2, 2023

REYKJAVIK, iceland, May 2, 2023 /PRNewswire/ -- TARAMAR, an award-winning beauty brand from Iceland is proud to be supporting Icelandic singer Diljá on her Eurovision 2023 journey. The company strongly believes in supporting young artists on their way to success. 

Key Points: 
  • The young star is a big fan of TARAMAR's natural and organic skincare line and the amazing benefits that pure Icelandic skincare delivers.
  • A spokesperson at TARAMAR said, "At TARAMAR, we know how stressful it can be being in the spotlight and the public eye.
  • To celebrate this epic event and collaboration, TARAMAR is proud to announce the launch of the TARAMAR Eurovision Gift Box .
  • Together with careful cultivation of plants and organic farming, the TARAMAR formulas may be among the purest skincare formula on the market.

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

Retrieved on: 
Monday, May 1, 2023

These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.

Key Points: 
  • These data were featured in a poster presentation (Poster #396) at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washington, D.C.
  • Results showed that patients with AD treated with Opzelura experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment.
  • "We are pleased that the SCRATCH-AD results further emphasize the rapid impact of Opzelura on itch reduction and reinforce its profile as an effective, well-tolerated topical non-steroidal treatment for AD."
  • “I am encouraged by these results showing rapid and substantial itch reduction among AD patients treated with Opzelura, and its potential to quickly alleviate this burdensome symptom for patients.”

New Eczema Study: 91% of Panelists See Relief Using Steroid-Free ARCTIVA™ Formulation

Retrieved on: 
Monday, May 1, 2023

The revolutionary new skincare product joins the market as one of the most effective steroid-free treatments for eczema and dermatitis.

Key Points: 
  • The revolutionary new skincare product joins the market as one of the most effective steroid-free treatments for eczema and dermatitis.
  • ARCTIVA Eczema Cream is the only product line on the market that features breakthrough HYDROSURF™ glycolipid technology—a powerful blend of fermented ingredients with origins from Antarctica.
  • Within the first seven days of the eczema panel, participants experienced significant relief of itching, redness and flaking.
  • "The longer people used the ARCTIVA Eczema Cream, the more relief they experienced," said Peroni.